Table 1:

Overview of literature reviews that will address research questions to inform the guideline

Question	Review type	Study designs included	Comparison	Follow-up duration (after baseline)	Potential outcomes^*	Potential subgroups and sensitivity analysis^*
1. What are values, preferences, perceptions, attitudes and beliefs of children and adolescents with obesity and their caregivers regarding the benefits and harms (in the context of important health-related outcomes) of obesity management strategies?	Systematic review	Any	NA	NA	Perceptions, experiences, attitudes, beliefs and expectations	Children, adolescents and parents Sex, gender Ethnicity, culture, SES Typical v. atypical growth and development (physical or cognitive delay or disability)
2. What tools, processes and procedures are recommended by expert groups for the clinical assessment of children and adolescents with obesity? What are the gaps in the existing guidelines?	Scoping review, with stakeholder consultation	Any	NA	NA	Edmonton Obesity Staging System for Pediatrics,23 including the 4 Ms (metabolic health, mental health, mechanical health and social milieu)	Children, adolescents, and parents Sex, gender Ethnicity, culture, SES Typical v. atypical growth and maturation (physical or cognitive delay or disability) Communication and terminology Weight bias and stigma Screening, enrolment and follow-up
3. Among children and adolescents with obesity, what is the effect of psychological and behavioural change interventions (see Appendix 1 for definition) on health outcomes deemed important to stakeholders, including families, clinicians and researchers?	Systematic review and meta-analysis	Randomized controlled trials	Any nonactive (e.g., wait-list control) or active (e.g., standard care) alternative management strategies	Immediate post and longest follow-up (closest to 12 mo)	Anthropometry (e.g., body weight, BMI, WC) Cardiometabolic risk factors (e.g., blood pressure, insulin resistance, HDL-C) Outcomes reported by patients or proxies (caregivers) (e.g., anxiety, depression, health-related quality of life) Adverse events	Age Weight status Sex, gender Risk of bias If we identify studies that reported data at ≥ 16 mo, we will assess the 12-mo estimate with and without these data
4. Among children and adolescents with obesity, what is the effect of pharmacotherapeutic interventions on health outcomes deemed important to stakeholders, including families, clinicians and researchers?	Systematic review and meta-analysis	Randomized controlled trials	Any nonactive (e.g., wait list control) or active (e.g., standard care) alternative management strategies	Immediate post and longest follow-up (closest to 12 mo)	Anthropometry (e.g., body weight, BMI, WC) Cardiometabolic risk factors (e.g., blood pressure, insulin resistance, HDL-C) Outcomes reported by patients or proxies (caregivers) (e.g., anxiety, depression, health-related quality of life) Adverse events	Age Weight status Sex, gender Risk of bias If we identify studies that reported data at ≥ 16 mo, we will assess the 12-mo estimate with and without these data
5. Among children and adolescents with obesity, what is the effect of bariatric surgery interventions on health outcomes deemed important to stakeholders, including families, clinicians and researchers?	Systematic review and meta-analysis	Randomized controlled trials, prospective or retrospective cohort studies and other observational studies	Any nonactive (e.g., wait list control) or active (e.g., standard care) alternative management strategies	For the weight outcomes up to 12 mo; 18-mo and longest follow-up; for other outcomes up to 18 mo	Anthropometry (e.g., body weight, BMI, WC) Cardiometabolic risk factors (e.g., blood pressure, insulin resistance, HDL-C) Outcomes reported by patients or proxies (caregivers) (e.g., anxiety, depression, health-related quality of life) Adverse events	Age Weight status Sex, gender Risk of bias If we identify studies that reported data at ≥ 16 mo, we will assess the 12-mo estimate with and without these data

Note: BMI = body mass index, HDL-C = high-density lipoprotein cholesterol, NA = not applicable, SES = socioeconomic status, WC = waist circumference.
↵* Potential outcomes and subgroups will be determined on the basis of data derived from surveys with stakeholders (parents, clinicians and researchers).